SMART (artificial intelligence enabled) DROP (diabetic retinopathy outcomes and pathways): Study protocol for diabetic retinopathy management

SMART(人工智能赋能)DROP(糖尿病视网膜病变结局和路径):糖尿病视网膜病变管理研究方案

阅读:2

Abstract

INTRODUCTION: Delayed diagnosis of diabetic retinopathy (DR) remains a significant challenge, often leading to preventable blindness and visual impairment. Given that physicians are frequently the first point of contact for people with diabetes, there is a critical need for integrated screening programs within diabetes clinics to enhance DR management and reduce the risk of severe vision loss. METHODS AND ANALYSIS: We will conduct a prospective cohort study comparing (i) the intervention cohort, screened at diabetes clinics and referred to eye clinics per the proposed pathway, and (ii) the standard-of-care (SOC) eye clinic cohort. The study will be conducted in Hyderabad, India, at LV Prasad Eye Institute and four IDEA (Institute of Diabetes, Endocrinology, and Adiposity) Clinics. The primary objective is to evaluate the effectiveness of a systematic diabetic retinopathy screening program in achieving earlier detection and reducing visual impairment among People With Diabetes (PWD) attending IDEA clinics compared to routine care at eye care settings. The screening program will be operationalized using AI-enabled tools and supported by trained non-medical technicians. We will perform visual acuity tests and non-mydriatic fundus photography using AI-assisted cameras. DR-positive patients will be referred for treatment and follow-up. We aim to achieve high accuracy (>90%) in appropriate referral of DR and high screening coverage (>80%) of eligible PWD. Success metrics include screening uptake, AI diagnostic accuracy, referral rates, cost-effectiveness, patient satisfaction, follow-up adherence, and long-term outcomes. CONCLUSION: This study aims to enhance diabetic retinopathy screening and management through an AI-enabled approach at diabetes clinics, improving early detection and care pathways. The findings will contribute to evidence-based strategies for optimizing DR screening and management, with results disseminated through peer-reviewed publications to inform policy and practice. TRIAL REGISTRATION: Trial registration number: CTRI/2024/03/064518 [Registered on: 20/03/2024] (https://ctri.nic.in/).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。